Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+

Tyler Patchen

News Reporter

Verastem Oncology inked a deal potentially worth up to $625.5 million with Chinese biotech GenFleet Therapeutics that aims to move three oncology programs into the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ve­rastem On­col­o­gy se­cures col­lab­o­ra­tion with Gen­Fleet Ther­a­peu­tics, po­ten­tial­ly worth up to $600M+

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+